# Pharmatrophix: Promoting Resilience in Neurodegenerative Diseases

> Alzheimer's and Neurodegenerative diseases damage brain connections\. PharmatrophiX developing drug targets synaptic resilience\.

Generated by Yoast SEO v28.1, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [Pipeline](https://pharmatrophix.com/pipeline/)
- [Home](https://pharmatrophix.com/)
- [Neurodegenerative Diseases](https://pharmatrophix.com/neurodegenerative-diseases/)
- [Research \& Development](https://pharmatrophix.com/research-development/)
- [About](https://pharmatrophix.com/about/)

## Posts
- [Dr\. Frank Longo, Stanford University professor of neurology and PharmatrophiX co\-founder, joins ‘Squawk Box’ to discuss the company’s new Alzheimer’s drug LM11A\-31, how the new drug approaches treatment differently from existing Alzheimer’s therapies, and more\.](https://pharmatrophix.com/dr-frank-longo-stanford-university-professor-for-neurology-and-pharmatrophix-co-founder-joins-squawk-box-to-discuss-the-companys-new-alzheimers-drug-lm11a-31-ho/)
- [Indiana University and PharmatrophiX Present Findings on Performance of Oral Therapeutic, LM11A\-31, to Reduce Decline of Brain Functional\-Network Connectivity in Alzheimer’s Disease](https://pharmatrophix.com/indiana-university-and-pharmatrophix-present-findings-on-performance-of-oral-therapeutic-lm11a-31-to-reduce-decline-of-brain-functional-network-connectivity-in-alzheimers-disease/)
- [Targeting Upstream Neurodegeneration: LM11A\-31 in Alzheimer's Disease and PSP](https://pharmatrophix.com/targeting-upstream-neurodegeneration-lm11a-31-in-alzheimer-disease-and-psp/): David Setboun, Pharm\.D\., MBA, CEO of PharmatrophiX, and Frank M\. Longo, MD, PhD, Co\-founder \& Chairman, discuss LM11A\-31’s upstream mechanism targeting p75 signaling and its potential to modify neurodegenerative disease biology\.
- [PharmatrophiX Selected for Landmark UCSF\-led platform trial in rare neurodegenerative disease; Unveils New Data at Tau Global Conference](https://pharmatrophix.com/pharmatrophix-selected-for-landmark-ucsf-led-platform-trial-in-rare-neurodegenerative-disease-unveils-new-data-at-tau-global-conference/): PharmatrophiX unveiled preclinical data at the Global Tau Conference further supporting evidence that LM11A\-31 is a multi\-action shield for the brain's connections
- [p75 receptor modulation slows biomarkers and preserves visuospatial function](https://pharmatrophix.com/phase-2-interim-data-for-lm11a-31-in-alzheimers/): CTAD coverage reports p\-tau217 and synaptic\-proteome signals over 26 weeks\.

## Team
- [Robert B\. Sims, M\.D\.](https://pharmatrophix.com/team/robert-sims/)
- [Louise F\. Brady](https://pharmatrophix.com/team/louise-f-brady/)
- [Anne Chun Longo](https://pharmatrophix.com/team/anne-chun-longo/)
- [Jeffrey L\. Cummings, M\.D\., Sc\.D\.](https://pharmatrophix.com/team/jeff-cummings/)
- [David Setboun, Pharm\.D\., MBA](https://pharmatrophix.com/team/david-setboun/)

## PR Funding and Investor
- [p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo\-controlled phase 2a trial](https://pharmatrophix.com/pr_funding_investor/p75-neurotrophin-receptor-modulation-in-mild-to-moderate-alzheimer-disease-a-randomized-placebo-controlled-phase-2a-trial/): Shanks H\.R\.C\. et al\. \- Nature Medicine \- 30, 1761\-1770 \(2024\)
- [Targeting Endogenous Mechanisms of Brain Resilience for the Treatment and Prevention of Alzheimer’s Disease](https://pharmatrophix.com/pr_funding_investor/targeting-endogenous-mechanisms-of-brain-resilience-for-the-treatment-and-prevention-of-alzheimers-disease/): Shanks H\.R\.C\., Onuska K\.M\., Massa S\.M\., Schmitz T\.W\., Longo F\.M\. \- J Prev Alz Dis \- 10\(4\), 699\-705 \(2023\)
- [New Study in Nature Medicine Shows Novel Neuroprotective Drug Candidate Meets Primary Endpoint in Patients with Mild to Moderate Alzheimer’s Disease](https://pharmatrophix.com/pr_funding_investor/new-study-in-nature-medicine-shows-novel-neuroprotective-drug-candidate-meets-primary-endpoint-in-patients-with-mild-to-moderate-alzheimers-disease/): Alzheimer’s Drug Discovery Foundation / PRNewswire \- May 17, 2024

## Categories
- [Publication](https://pharmatrophix.com/category/publication/)
- [Clinical](https://pharmatrophix.com/category/clinical/)
- [Corporate](https://pharmatrophix.com/category/corporate/)

## Tags
- [INDIANA UNIVERSITY AND PHARMATROPHIX PRESENT FINDINGS ON PERFORMANCE OF ORAL THERAPEUTIC](https://pharmatrophix.com/tag/indiana-university-and-pharmatrophix-present-findings-on-performance-of-oral-therapeutic/)
- [Nature Medicine](https://pharmatrophix.com/tag/nature-medicine/)
- [Press release](https://pharmatrophix.com/tag/press-release/)
- [Review](https://pharmatrophix.com/tag/review/)
- [Peer\-reviewed](https://pharmatrophix.com/tag/peer-reviewed/)

## Team Category
- [Executive Team](https://pharmatrophix.com/team-categories/executive-team/)
- [Scientific Advisory Board](https://pharmatrophix.com/team-categories/scientific-advisory-board/)

## PR Funding and Investor Category
- [Peer\-Reviewed Publications](https://pharmatrophix.com/pr-funding-investor-categories/peer-reviewed-publications/)
- [Press Releases](https://pharmatrophix.com/pr-funding-investor-categories/press-releases/)

## Optional
- [Sitemap index](https://pharmatrophix.com/sitemap_index.xml)